SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities | Global Health | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities Across Multiple Regions in the United States

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Can severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks occur simultaneously across culturally bound minority communities?

Findings  In this cross-sectional study of 9507 ambulatory adults, a near simultaneous surge in coronavirus disease 2019 symptom onset and high seroprevalence in as many as 32.5% community members were found among geographically distinct yet culturally bound religious communities. This surge corresponded to social events surrounding the festival of Purim, prior to widespread recognition of epidemic mitigation strategies.

Meaning  These findings suggest that parallel outbreaks may occur within culturally bound communities during holiday periods, which could be exacerbated in the absence of national, culturally sensitive guidance.

Abstract

Importance  Data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in the United States are still emerging.

Objective  To elucidate SARS-CoV-2 seroprevalence and symptom onset in a culturally linked community across 5 states in the United States.

Design, Setting, and Participants  This cross-sectional study included adults (aged ≥18 years) recruited from the orthodox Jewish community across 5 states (California, Connecticut, Michigan, New Jersey, and New York) in 3 geographically distinct areas of the United States between May 13 and July 6, 2020. Participants completed an online survey and underwent SARS-CoV-2 antibody testing.

Main Outcomes and Measures  Seroprevalence and date of symptom onset of SARS-CoV-2.

Results  Overall, 9507 adults (mean [SD] age, 39.6 [15.0] years; 3777 [39.7%] women) completed the SARS-CoV-2 survey, of whom 6665 (70.1%) had immunoglobin G anti–SARS-CoV-2 antibody levels assessed. A high seroprevalence of SARS-CoV-2 antibodies was observed across all communities, with the highest proportion of positive testing observed in New Jersey (1080 of 3323 [32.5%]) and New York (671 of 2196 [30.6%]). Most individuals with a positive SARS-CoV-2 immunoglobin G antibody test reported a date of symptom-onset between March 9 and March 31, 2020 (California: 135 of 154 [87.7%]; Connecticut: 32 of 34 [94.1%]; Michigan: 44 of 50 [88.0%]; New Jersey: 964 of 1168 [82.5%]; New York: 571 of 677 [84.3%]). This start date was coincident with the Jewish festival of Purim, celebrated March 9 to 10, 2020, with extensive intracommunity spread in the weeks following (mean and mode of peak symptom onset, March 20, 2020), occurring in the absence of strong general and culture-specific public health directives.

Conclusions and Relevance  This cross-sectional study of orthodox Jewish adults across the US found that socioculturally bound communities experienced early parallel outbreaks in discrete locations, notably prior to substantive medical and governmental directives. Further research should clarify optimal national, local, community-based, and government policies to prevent outbreaks in social and cultural communities that traditionally gather for holidays, assemblies, and festivals.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: February 1, 2021.

Published: March 10, 2021. doi:10.1001/jamanetworkopen.2021.2816

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Zyskind I et al. JAMA Network Open.

Corresponding Authors: Jonathan I. Silverberg, MD, PhD, MPH, Department of Dermatology, George Washington University, 2150 Pennsylvania Ave NW, Ste 2B-425, Washington, DC 20037 (jonathanisilverberg@gmail.com); Avi Z. Rosenberg, MD, PhD, Department of Pathology, Johns Hopkins University, 720 Rutland Ave, Ross Bldg, Room 632D, Baltimore, MD 21205 (arosen34@jhmi.edu).

Author Contributions: Dr Silverberg had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Zyskind and Rosenberg contributed equally to the work. Drs Rosenberg and Silverberg are co–senior authors.

Concept and design: Zyskind, Rosenberg, Zimmerman, Glatt, Joyner, Lieberman, Bigajer, Stok.

Acquisition, analysis, or interpretation of data: Zyskind, Rosenberg, Zimmerman, Naiditch, Glatt, Pinter, Theel, Joyner, Hill, Bigajer, Stok, Frank, Silverberg.

Drafting of the manuscript: Zyskind, Rosenberg, Naiditch, Glatt, Pinter, Silverberg.

Critical revision of the manuscript for important intellectual content: Rosenberg, Zimmerman, Naiditch, Glatt, Theel, Joyner, Hill, Lieberman, Bigajer, Stok, Frank, Silverberg.

Statistical analysis: Rosenberg, Naiditch, Silverberg.

Administrative, technical, or material support: Zyskind, Rosenberg, Zimmerman, Naiditch, Pinter, Theel, Joyner, Hill, Lieberman, Bigajer, Stok, Frank, Silverberg.

Supervision: Zyskind, Rosenberg, Zimmerman, Glatt, Lieberman, Silverberg.

Conflict of Interest Disclosures: Dr Theel reported receiving personal fees from Roche Diagnostics Advisory Board and Accelerate Diagnostics Consulting outside the submitted work. Dr Hill reported performing coronavirus disease 2019 tests for ResourcePath outside the submitted work. No other disclosures were reported.

Funding/Support: Grant 1R35HL139854 from the National Heart, Lung, and Blood Institute and gifts from the National Basketball Association and United Health Group (Dr Joyner) supported the design and conduct of the study.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: The following organizations and individuals gave much of their time and expertise to organize the onboarding and testing of the nearly 7000 participants in this study: The Mayo Clinic, The Gates Foundation, Streamline Verify, DealMed, Lakewood Bikur Cholim (Yehudah Kaszirer, BA, Leeba Lederer, Shlomo Ingber, MBL, Chaim Lichtenstein, BTL, Avromi Millworm, Raizy Werner, Levi Friedman, Yehoshua Lapidus), Duvy Perkowski, BTL, Boruch Ber Bender, BTL, and Achiezer Staff, Shalom Jaroslowitz, MSN, FNP, Stellar Scientific, Yankee Friedman, MBA, Joseph Zyskind, Flatbush Hatzolah Volunteer Corps, Chasky Rosenberg, Los Angeles Hatzolah Volunteer Corps, Sarah Weisshaus, RN, BSN, Leon Freue, BA, NREMT-P, Aron Rothman, BS, NRP, Aryeh Edell, Yitzchok Rabinowitz, NREMT-P, Robbie Zeitz, BA, Avi Gantz, Debra Stok, LMSW, Judy Zyskind, DDS, Detroit Hatzolah, Nachi Soloff, Lou Scheiner, and Chaim Einhorn, BS. None of these individuals were compensated for their time.

References
1.
Cucinotta  D , Vanelli  M .  WHO declares COVID-19 a pandemic.   Acta Biomed. 2020;91(1):157-160.PubMedGoogle Scholar
2.
Holshue  ML , DeBolt  C , Lindquist  S ,  et al; Washington State 2019-nCoV Case Investigation Team.  First case of 2019 novel coronavirus in the United States.   N Engl J Med. 2020;382(10):929-936. doi:10.1056/NEJMoa2001191PubMedGoogle ScholarCrossref
3.
Elmore  JG , Wang  PC , Kerr  KF ,  et al.  Excess patient visits for cough and pulmonary disease at a large US health system in the months prior to the COVID-19 pandemic: time-series analysis.   J Med Internet Res. 2020;22(9):e21562. doi:10.2196/21562PubMedGoogle Scholar
4.
Cheng  HY , Jian  SW , Liu  DP , Ng  TC , Huang  WT , Lin  HH ; Taiwan COVID-19 Outbreak Investigation Team.  Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset.   JAMA Intern Med. 2020;180(9):1156-1163. doi:10.1001/jamainternmed.2020.2020PubMedGoogle ScholarCrossref
5.
Zhang  J , Litvinova  M , Liang  Y ,  et al.  Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China.   Science. 2020;368(6498):1481-1486. doi:10.1126/science.abb8001PubMedGoogle ScholarCrossref
6.
Hamner  L , Dubbel  P , Capron  I ,  et al.  High SARS-CoV-2 attack rate following exposure at a choir practice—Skagit County, Washington, March 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(19):606-610. doi:10.15585/mmwr.mm6919e6PubMedGoogle ScholarCrossref
7.
Quadri  SA .  COVID-19 and religious congregations: implications for spread of novel pathogens.   Int J Infect Dis. 2020;96:219-221. doi:10.1016/j.ijid.2020.05.007PubMedGoogle ScholarCrossref
8.
Atique  S , Itumalla  R .  Hajj in the time of COVID-19.   Infect Dis Health. 2020;25(3):219-221. doi:10.1016/j.idh.2020.04.001PubMedGoogle ScholarCrossref
9.
Ebrahim  SH , Memish  ZA .  Saudi Arabia’s drastic measures to curb the COVID-19 outbreak: temporary suspension of the Umrah pilgrimage.   J Travel Med. 2020;27(3):taaa029. doi:10.1093/jtm/taaa029PubMedGoogle Scholar
10.
Pew Research Center. A portrait of American orthodox Jews: a further analysis of the 2013 Survey of U.S. Jews. Published August 26, 2015. Accessed January 28, 2021. https://www.pewforum.org/wp-content/uploads/sites/7/2015/08/Orthodox-Jews-08-24-PDF-for-web.pdf
11.
Theel  ES , Harring  J , Hilgart  H , Granger  D .  Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2.   J Clin Microbiol. 2020;58(8):e01243-20. doi:10.1128/JCM.01243-20PubMedGoogle Scholar
12.
Stadlbauer  D , Tan  J , Jiang  K ,  et al.  Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City.   Nature. 2021;590(7844):146-150. doi:10.1038/s41586-020-2912-6PubMedGoogle ScholarCrossref
13.
Havers  FP , Reed  C , Lim  T ,  et al.  Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.   JAMA Intern Med. 2020;180(12):1576-1586. doi:10.1001/jamainternmed.2020.4130PubMedGoogle ScholarCrossref
14.
Baker  JO , Martí  G , Braunstein  R , Whitehead  AL , Yukich  G .  Religion in the Age of Social Distancing: How COVID-19 Presents New Directions for Research.   Sociol Religion. 2020;81(4):357-370. doi:10.1093/socrel/sraa039Google ScholarCrossref
15.
Shariff  AF , Willard  AK , Andersen  T , Norenzayan  A .  Religious priming: a meta-analysis with a focus on prosociality.   Pers Soc Psychol Rev. 2016;20(1):27-48. doi:10.1177/1088868314568811PubMedGoogle ScholarCrossref
16.
Henderson  S , Kendall  E , See  L .  The effectiveness of culturally appropriate interventions to manage or prevent chronic disease in culturally and linguistically diverse communities: a systematic literature review.   Health Soc Care Community. 2011;19(3):225-249. doi:10.1111/j.1365-2524.2010.00972.xPubMedGoogle ScholarCrossref
17.
Miller  AC , Castro Bigalli  AA , Sumanam  P .  The coronavirus disease-2019 pandemic, social distancing, and observance of religious holidays: perspectives from Catholicism, Islam, Judaism, and Hinduism.   Int J Crit Illn Inj Sci. 2020;10(2):49-52. doi:10.4103/IJCIIS.IJCIIS_60_20PubMedGoogle ScholarCrossref
18.
World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19—11 March 2020. Published March 11, 2020. Accessed February 4, 2021. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
19.
Schuchat  A ; CDC COVID-19 Response Team.  Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24-April 21, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(18):551-556. doi:10.15585/mmwr.mm6918e2PubMedGoogle ScholarCrossref
20.
Bajema  KL , Wiegand  RE , Cuffe  K ,  et al.  Estimated SARS-CoV-2 seroprevalence in the US as of September 2020.   JAMA Intern Med. Published online November 24, 2020. doi:10.1001/jamainternmed.2020.7976PubMedGoogle Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close